The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 10, 2005, Pages 5698-5703

  Saely, Christoph H ^a,b   Aczel, Stefan ^a,b   Marte, Thomas ^a,b   Langer, Peter ^a   Hoefle, Guenter ^b   Drexel, Heinz ^a,b,c  

^a Vorarlberg Institute for Vascular Investigation and Treatment   (Austria)

^b ACADEMIC TEACHING HOSPITAL FELDKIRCH   (Austria)

^c NONE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL RESEARCH; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; VASCULAR DISEASE;

AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; CORONARY ANGIOGRAPHY; DIABETES MELLITUS, TYPE 2; FEMALE; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 26244446897     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-0799     Document Type: Article

References (33)

1. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP 1992 Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 41:715-722
2. Resnick HE, Jones K, Ruotolo G, Jain AK, Henderson J, Lu W, Howard BV 2003 Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care 26:861-867
3. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J 2003 Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108:414-419
4. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Wilson PW 2004 C-Reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110:380-385
5. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT 2002 The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709-2716
6. Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, Mannarino E 2004 Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 43:1817-1822
7. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L 2001 Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683-689
8. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Bonadonna RC, Muggeo M 2003 Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care 26:1251-1257
9. Ridker PM, Buring JE, Cook NR, Rifai N 2003 C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107:391-397
10. Katzmarzyk PT, Church TS, Janssen I, Ross R, Blair SN 2005 Metabolic syndrome, obesity, and mortality: impact of cardiorespiratory fitness. Diabetes Care 28:391-397
11. Adult Treatment Panel III 2001 Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497
12. Hanley AJ, Karter AJ, Festa A, D'Agostino Jr R, Wagenknecht LE, Savage P, Tracy RP, Saad MF, Haffner S 2002 Factor analysis of metabolic syndrome using directly measured insulin sensitivity: The Insulin Resistance Atherosclerosis Study. Diabetes 51:2642-2647
13. Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES 2004 Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 53:1195-1200
14. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, Shofer JB, Fish BE, Knopp RH, Kahn SE 2004 Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 53:2087-2094
15. Hanley AJ, Wagenknecht LE, D'Agostino Jr RB, Zinman B, Haffner SM 2003 Identification of subjects with insulin resistance and β-cell dysfunction using alternative definitions of the metabolic syndrome. Diabetes 52:2740-2747
16. Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A, Cacciatori V, Santi L, Targher G, Bonadonna R, Muggeo M 2002 HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 25:1135-1141
17. Bressler P, Bailey SR, Matsuda M, DeFronzo RA 1996 Insulin resistance and coronary artery disease. Diabetologia 39:1345-1350
18. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, Selby JV, Saad MF, Savage P, Bergman R 1996 Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) investigators. Circulation 93:1809-1817
19. Girman CJ, Rhodes T, Mercuri M, Pyorala K, Kjekshus J, Pedersen TR, Beere PA, Gotto AM, Clearfield M 2004 The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/Tex-CAPS). Am J Cardiol 93:136-141
20. Marroquin OC, Kip KE, Kelley DE, Johnson BD, Shaw LJ, Bairey Merz CN, Sharaf BL, Pepine CJ, Sopko G, Reis SE 2004 Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women's Ischemia Syndrome Evaluation. Circulation 109:714-721
21. Drexel H, Aczel S, Marte T, Benzer W, Langer P, Moll W, Saely CH 2005 Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care 28:101-107
22. Drexel H, Amann FW, Rentsch K, Neuenschwander C, Luethy A, Khan SI, Follath F 1992 Relation of the level of high-density lipoprotein subfractions to the presence and extent of coronary artery disease. Am J Cardiol 70:436-440
23. Drexel H, Amann FW, Beran J, Rentsch K, Candinas R, Muntwyler J, Luethy A, Gasser T, Follath F 1994 Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis. Circulation 90:2230-2235
24. Alberti KG, Zimmet PZ 1998 Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539-553
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
26. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M 2000 Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23:57-63
27. Stamler J, Vaccaro O, Neaton JD, Wentworth D 1993 Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434-444
28. Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A, Gemma L, Santi L, Bonadonna RC, Muggeo M 2004 The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med 21:52-58
29. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Runzo C, Prina CS, Pagano G, Cavallo-Perin P 2004 Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 27:2689-2694
30. Reaven GM 1988 Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595-1607
31. Reilly MP, Wolfe ML, Rhodes T, Girman C, Mehta N, Rader DJ 2004 Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation 110:803-809
32. Stern MP, Williams K, Hunt KJ 2005 Impact of diabetes/metabolic syndrome in patients with established cardiovascular disease. Atherosclerosis 6(Suppl):3-6
33. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A 2004 The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 27:1647-1653